Oral Cholecystographic Contrast Agents has 5 known drug interactions based on U.S. FDA drug labeling data. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Betamethasone Sodium Phosphate, Betamethasone Acetate, Lidocaine, Iodixanol, Povidine Iodine, Iodixanol, Ioversol. Patients taking Oral Cholecystographic Contrast Agents should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 5
- Major
- 4
- Moderate
- 1
Major (4)
- Oral Cholecystographic Contrast Agents + Betamethasone Sodium Phosphate, Betamethasone Acetate, Lidocaine, Iodixanol, Povidine Iodine— Renal toxicity reported in patients with liver dysfunction receiving oral cholecystographic agent followed by iodixanol.…
- Oral Cholecystographic Contrast Agents + Iodixanol— Renal toxicity reported in patients with liver dysfunction receiving oral cholecystographic agent followed by iodixanol.…
- Oral Cholecystographic Contrast Agents + Ioversol— Renal toxicity reported in patients with liver impairment given oral cholecystographic agents followed by intravascular …
- Oral Cholecystographic Contrast Agents + Levothyroxine Sodium— Iodine-containing agents may decrease or increase thyroid hormone secretion. Parenterally administered agents cause shor…
Moderate (1)
- Oral Cholecystographic Contrast Agents + Sodium Iodide I 131— Radiographic contrast agent that interferes with radioiodide accumulation. Discontinue 6 months before procedure.